{
    "nctId": "NCT01742117",
    "officialTitle": "Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)",
    "Criteria": "Inclusion\n\n* Patient \\>18 years of age\n* Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD)\n* Patient is eligible for PCI\n* Patient is willing and able to provide informed written consent\n\n5.3 Exclusion\n\n* Patient not able to receive 12 months of dual anti-platelet therapy\n* Failure of index PCI\n* Patient or physician refusal to enroll in the study\n* Patient with known CYP2C19 genotype prior to randomization\n* Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure\n* Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery\n* Serum creatinine \\>2.5 mg/dL within 7 days of index procedure\n* Platelet count \\<80,000 or \\>700,000 cells/mm3, or white blood cell count \\<3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.\n* History of intracranial hemorrhage\n* Known hypersensitivity to clopidogrel or ticagrelor or any of its components\n* Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint\n* Patient previously enrolled in this study\n* Patient is pregnant, lactating, or planning to become pregnant within 12 months\n* Patient has received an organ transplant or is on a waiting list for an organ transplant\n* Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure\n* Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.)\n* Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)\n* Concomitant use of simvastatin/lovastatin \\> 40 mg qd\n* Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)\n* Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer)\n* Known history of severe hepatic impairment\n* Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions\n* Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding\n* Inability to take aspirin at a dosage of 100 mg or less\n* Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)",
    "inclusionCriteria": "\n* Must have minimum age of 18 Years"
}